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Abstract
Background: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating
syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different
therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.
Methods: This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged
≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated
patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we
assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and
on/end-treatment.
Results: Median age at onset was 34.1 years (range 18.0–67.1), the female to male ratio was 1.2:1, and 96% were
Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1–89.8) patients relapsed. At the last follow-up, 66 (52.8%)
received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF],
rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20–0.82; p = 0.011).
Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from
1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012).
Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-
modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS
progression were observed with azathioprine, MMF or rituximab.
Conclusion: In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and
rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the
few patients treated with MS-DMD.
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Background
Myelin oligodendrocyte glycoprotein (MOG) antibody
(Ab)-associated diseases are increasingly recognised as a
distinct entity from either multiple sclerosis (MS) and
aquaporin-4 (AQP4)-Ab-associated disease [1–7]. In adults,
MOG-Ab has been found in patients with acquired demye-
linating syndromes (ADS), including neuromyelitis optica
spectrum disorders (NMOSD), limited forms related to the
spectrum (optic neuritis [ON], transverse myelitis [TM]),
encephalitis or brainstem syndromes [8–15].
Although initially MOG-Ab were mainly described in
patients with a monophasic course with mild prognosis
[1, 2, 4], recent studies reported a greater proportion of
patients with a relapsing course and even a fulminant
course with permanent disability [13, 16]. Moreover,
whether relapses contribute to long-term disability in
adults is under debate, since only a few studies have fo-
cused on relapsing patients and most of them included
paediatric cohorts [17, 18].
Given that MOG-Ab-associated disease is a relatively
new entity, physicians usually have some degree of un-
certainty on how to manage these patients [2, 19]. Stud-
ies mixing paediatric and adult populations have shown
that MOG-Ab-positive patients seem to be highly re-
sponsive to corticosteroids (CS) with an increased risk of
relapse when tapering or following discontinuation [9,
16, 18]. However, long-term treatment with CS is limited
by side effects underlying the need for steroid-sparing
drugs. A recent study of paediatric patients with relaps-
ing disease showed a reduction in relapse frequency as-
sociated with B cell-targeted therapies or intravenous
immunoglobulins (IVIG) but not with MS disease-
modifying drugs (MS-DMD) [17]. A beneficial effect of
immunosuppressants (IS) and CS but not on MS-DMD
has been reported in a case series [16]. However, more
systematic studies in adults with MOG-Ab-associated
disease dedicated to evaluate therapy strategies in real
life have not been performed so far. In rare diseases such
as NMOSD, clinical trials to measure treatment response
are difficult to perform and the information is usually
provided by observational studies [20, 21]. However,
such studies are known to be influenced by potential
bias. In this sense, the propensity score (PS) methods are
the most common devices used to reduce bias when
evaluating the effect of treatments on outcomes [22, 23].
We therefore conducted a retrospective multicentre
study to describe the response to different therapeutic




We retrospectively recruited patients from all French
and Spanish referral centres for neuroinflammatory
disorders, within the scope of the observatoire français
de la sclérose en plaques (OFSEP), and Red Española de
Esclerosis Múltiple (REEM) that fulfilled the following
inclusion criteria: (1) diagnosis of a relapsing ADS, de-
fined as at least two acute clinical demyelinating epi-
sodes of the central nervous system (CNS) persisting
for a minimum of 24 h; (2) age ≥ 18 years at onset of
disease; (3) presence of MOG-Ab in serum and absence
of aquaporin 4-Ab detected either at onset of disease or
during follow-up.
Clinical and therapeutic data
Clinical data already collected as part of both national
programmes were de-identified, and merged in a new
database. Epidemiological characteristics (sex, age at dis-
ease onset, ethnicity and country of provenience), clinical
characteristics (phenotype at onset, date of conversion to
NMOSD, severity at onset and last follow-up evaluated
with the Expanded Disability Status Scale [EDSS]), im-
aging abnormalities (≥ 1 lesion on T2-weighted sequences)
on the first brain magnetic resonance imaging (MRI), and
cerebrospinal fluid (CSF) characteristics (cell count [pleio-
cytosis > 5 cells/mm3], oligoclonal bands [OCB] and IgG
index) were included. For ON, visual acuity (VA) was eval-
uated by the visual functional system at the last follow-up
in patients experiencing any ON.
At the end of the follow-up, patients were assigned to
one of the following diagnostic categories; NMOSD-like
phenotype fulfilling 2015 criteria [24], MS-like pheno-
type in those fulfilling McDonald 2010 criteria [25], re-
lapsing ADS in a single CNS area (i.e. relapsing ON or
TM) or multiphasic acute disseminated encephalomyeli-
tis (MADEM) [24, 26]. Patients with short TM and ON
who did not strictly fulfil NMOSD criteria were classi-
fied as optico-spinal phenotype [24].
Acute treatment such as oral or IV CS, plasma ex-
change (PLEX) or IVIG was noted at the first episode.
Based on treatment experience [27], cumulative avail-
ability of clinical data as well as first- and second-line
therapy recommendations [28], we classified azathio-
prine (AZT), mycophenolate mophetil (MMF) and ritux-
imab (RTX) as type I IS, and cyclophosphamide (CYC),
methotrexate (MTX) and mitoxantrone (MiTX) as type
II IS. Long-term CS or IVIG was classified as type III IS
[28]. Beta-interferon, glatiramer acetate, teriflunomide,
natalizumab or fingolimod was classified as MS-DMD.
Treatment regimens are depicted in Additional file 1:
Table S1).
Based on pharmacodynamics and previous treatment
experience, patients treated for at least 6 months were
included in the treated group, and if not, they were in-
cluded in the non-treated group. Reason for discontinu-
ing treatment was also collected. In this retrospective
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study, the choice of treating was based upon the neurol-
ogists’ choice.
Cell-based assays
AQP4-Ab and MOG-Ab tests were performed in the Lyon
Neuroscience Research Center (France) and the Institut
d’Investigació Biomèdica August Pi i Sunyer of Barcelona
(Spain), by live cell-based assays (CBA) and using the pro-
tocols and plasmids as reported elsewhere [8, 29].
Statistical analysis
We first described the clinical features of the total co-
hort. To describe probabilities of first relapse or
NMOSD conversion in the whole cohort and according
to clinical phenotype at the onset, we performed
Kaplan-Meier survival analysis (with 95% of confidence
interval, 95%CI) using time from onset of disease (first
episode) to first relapse or NMOSD conversion.
To evaluate treatment response, we considered two stat-
istical methods:
Analysis 1. In order to study the effectiveness of
treatments in a group of comparable patients and to
limit treatment-related indication bias, we defined an
ambivalence clause that allowed us to create a base-
line date at which all patients had the opportunity to
receive treatment. We assumed that all patients at
diagnosis of relapsing ADS (at first relapse) were
likely to receive treatment. Thus, we defined the base-
line date (T0) as the date of treatment initiation for
treated patients and as the date of relapsing ADS
diagnosis (date of first relapse) for non-treated pa-
tients. We eliminated from the analysis patients initi-
ating treatment before diagnosis of relapsing ADS in
order to reduce a possible underestimation bias on
treatment effect (Fig. 1). To measure the effect of
treatments, the following possible confounders were
taken into consideration: sex, age at onset, ethnicity,
time between onset and the first relapse, phenotype
at onset, EDSS at nadir, abnormal first brain MRI and
country of provenience. Only confounders with p
value < 0.20 were included in the construction of the
PS model. The PS method based on the inverse probabil-
ity of treatment weighting (IPTW) was used to estimate
confounder-adjusted absolute risks in both treated and
non-treated groups. This method balances the two groups
to make them comparable across all confounders. With
this approach, we modelled how the probability of receiv-
ing treatment depends on the confounders. For each pa-
tient, the PS was the individual predicted probability to
receive the treatment according to baseline confounding
variables, and obtained by binary logistic regression using
the treatment group as outcome. The weight was the ratio
between the mean probability to receive the treatment
and the individual predicted probability to receive this
treatment. Then, a weighted Cox proportional hazards
model was used to estimate the effect of treatment on the
outcome. To compare different treatments to non-treated
patients, we calculated a PS for each comparison [22, 23].
For the analysis, an intention-to-treat strategy was used.
Analysis 2. Pre-treatment and on-treatment annualised
relapse rates (ARR) for each patient were calculated
(after excluding the index event). EDSS pre-treatment
(the closest EDSS to the initiation date of treatment and
sustained for at least 6 months) and end-treatment (the
closest EDSS to end of treatment date and sustained for
at least 6 months) were also evaluated. Similarly, VA pre-
treatment and end-treatment were also noted. We ex-
clude any transient worsening of disability related to re-
lapses when measuring EDSS or VA. ARR, EDSS and
VA were calculated for patients with at least 6 months of
follow-up (Fig. 1).
Fig. 1 Flow chart of relapsing MOG-Ab adult patients included in different analyses
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If the same drug was given recurrently with a latency
of > 3 months between 2 cycles, only the time from the
first to the last drug application of the first cycle was
considered and the other cycles with the same drug were
rejected. This was observed for AZT, MMF and MS-
DMD. For the other treatments, no recurrent treatment
episodes were observed with the exception of one pa-
tient treated with type II IS (CYC followed by MTX
1 year apart). In this case, the first treatment period was
considered for the analysis.
Wilcoxon’s matched-pairs rank sum test was used to
compared ARR, EDSS and VA pre-treatment and on/
end-treatment, and results were given as mean and
standard deviation (SD). Only treatments with ≥ 5 pa-
tients who fulfilled the inclusion criteria were eligible for
the analysis.
All statistical analyses were performed using STATA-
12 (64-bits) software and a p value < 0.05 was considered
significant. Graphs were constructed with GraphPad
Prism (version 5.0) or R-3.4.4. Due to the exploratory
nature of the study, we did not correct for multiple com-
parisons in either of the analyses.
Results
Cohort description
Clinical features at first episode
We identified 125 patients with relapsing MOG-Ab-
associated disease. Median age at onset was 34.1 years
(range 18.0–67.1), and the median duration of disease was
4.5 years (interquartile range [IQR], 1.8–10.2). Patients were
mainly Caucasian (n = 120, 96.0%) with a female to male ra-
tio of 1.2:1.0. Clinical phenotype at onset was characterised
by ON in 82 (65.6%) patients, myelitis in 25 (20%) and ON
together with myelitis in 9 (7.2%). Encephalopathic or brain-
stem syndromes were found in 9 (7.2%) patients. Among
paraclinical features, 41/98 (41.8%) had pleiocytosis and 10/
107 (9.4%) had OCB in the CSF. The first brain MRI
showed abnormalities in 28/74 (37.8%) patients.
The diagnosis at the last follow-up was relapsing ON
in 61 (48.8%) patients, NMOSD-like phenotype in 41
(32.8%) and relapsing TM in 11 (8.8%; 5 patients had ex-
tensive TM [LETM]), optico-spinal phenotypes in 4
(3.2%) and relapsing brainstem syndrome in 2 (1.6%).
MADEM (all with ON relapses; ADEM-ON) was diag-
nosed in 3 (2.4%) patients, and MS-like phenotype in 3
(2.4%) patients (Table 1 and Additional file 1: Table S2
for features of MS patients).
Clinical course of disease
One hundred twenty (96%) patients received acute treat-
ment at the onset. At last follow-up, 66 (52.8%) patients re-
ceived maintenance therapy ≥ 6months at some point; 47
(71.2%) patients were treated with one treatment, 15
(22.7%) with two treatments and 4 (6.1%) with three treat-
ments. Among the 66 treated patients, only 9 (13.6%) initi-
ated maintenance therapy before the first relapse (Fig. 2).
EDSS at onset from these 9 patients did not differ from pa-
tients starting maintenance therapy after the first relapse
(p= 0.175). At the first episode, PLEX and IVIG were more
often prescribed in patients who further received mainten-
ance therapy than in those without such treatment (16/66
[24.2%] vs. 3/59 [5.1%]), respectively, p= 0.003).
The majority of patients had good recovery at the last
follow-up; 86 (69.9%) had mild (EDSS ≤ 2.5), 31 (25.2%)
moderate (EDSS 3–5.5) and 6 (4.9%) severe disability
(EDSS ≥ 6.0). Sixty one out of 100 (61%) patients with
ON during the disease course had mild (VA ≥ 0.7), 21
(21%) moderate (0.2–0.6) and 18 (18%) severe VA dis-
ability at the last follow-up (Table 1).
A total of 438 demyelinating events were reported. The
median number of relapses was 2 (IQR, 1–3). Patients who
presented ≥ 2 relapses had higher EDSS at the last follow-
up (median 2 [IQR, 1–3] than those with 1 relapse (median
1.5 [IQR 0–3]), p = 0.022, (Wilcoxon signed-rank test).
Within the first year, 56% (95%CI, 47.6–64.8) of patients
relapsed. At 2 years, 68% had relapsed (95%CI, 59.8–76.0),
and at 5 years, 84% had done so (95%CI, 77.1–89.8)
(Fig. 3a). Clinical phenotype at onset of symptoms was not
related to relapse risk (Additional file 2: Figure S1A).
However, at 2 years a greater proportion of patients pre-
senting with TM at onset were diagnosed with NMOSD
(38.2% [95%CI, 20.8–63.0]) than ON (17.3% [95%CI, 8.9–
32.4]; Log-rank p = 0.032; Additional file2; Figure S1B).
Treatment responses
Analysis 1: relapse risk according to treatment
Comparison of baseline possible confounders between
treated and non-treated patients in the original sample
and the pseudo-population weighting by PS are shown
in (Additional file 1: Table S3 and S4).
PS-weighted survival analysis found that the 2-year
risk of relapse was 49.9% (95%CI, 44.2–56.0) for the 59
non-treated patients compared to 38.6% (95%CI, 34.6–
42.9) for the 57 treated patients (Fig. 3b). The 2 year-risk
of relapse was 52.1% (95%CI, 46.3–58.1) for the 59 non-
treated patients compared to 19.4% (95%CI, 15.7–23.9)
for the 40 type I IS-treated patients (Fig. 3c). The slight
difference between the two analyses for the non-treated
group is due to the different PS used for each model.
Although relapse rate was significantly lower in
treated than in non-treated patients (HR, 0.58; 95%CI,
0.34–0.99; p = 0.050) when performing the crude ana-
lysis, the difference was no longer significant after PS
weighting (HR, 0.68; 95%CI, 0.40–1.16; p = 0.155).
Type I IS-treated patients were at significantly lower
risk of relapse (HR, 0.40; 95%CI, 0.21–0.77; p = 0.006)
than non-treated patients, and this difference was still
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present after PS weighting (HR, 0.41; 95CI%, 0.20–
0.82; p = 0.011; Table 2). PS-weighted proportional
hazards Cox models were not used in the other
groups due to the low number of patients.
Three out of 15 (20%) patients starting with AZT, 0 out 6
patients with MMF and 2 out of 17 (10.5%) starting with
RTX relapsed within the first 6months after starting re-
spective treatments.
Analysis 2: annualised relapse ratio and disability according
to treatments
Overall, 49/66 (74.2%) treated patients received AZT,
MMF, or RTX (≥ 6 months each) at any time.
Azathioprine
AZT was given to 19/66 (28.8%) treated patients at any
time; 15 of them (78.9%) received AZTas first-line therapy



















Females, n (%) 69 (55.2) 33 (54.1) 24 (58.5) 5 (45.5) 3 (60) 4 (57.1)






34.6 (18.0–62.5) 33.7 (18.0–
42.1)
45.7 (31.3–60.7) 22.7 (19.4–53.7)
Caucasian, n (%) 120 (96) 58 (95.1) 40 (97.6) 11 (100) 5 (100) 6 (85.7)
Follow-up, years, median (range) 4.5 (0.2–47) 1.4 (0.4–47) 5.7 (0.2–47) 10.9 (2.1–
21.2)
2.5 (0.56–4.0) 5.5 (0.2–19.3)
Phenotype at onset, n (%)
ON 82 (65.6) 61 (100) 16 (39) 0 0 5 (71.4)
Myelitis 25 (20) 0 12 (29.3) 11 (100) 0 2 (28.6)
ON and myelitis 9 (7.2) 0 9 (22) 0 0 0
Encephalopathic/brainstem S. 9 (7.2) 0 4 (9.7) 0 5 (100) 0
EDSS at onset, median (range) 3 (0–9) 2.5 (0–4) 3.25 (0–7.5) 3 (1–6) 4.5 (3.5–9) 3.5 (3–8)
EDSS 0–2.5 47 (38.2) 30 (50) 22 (55) 4 (36.6) 3 (60) 5 (71.4)
EDSS 3–5.5 64 (52) 30 (50) 32 (55) 4 (36.6) 3 (60) 5 (71.3)
EDSS ≥ 6.0 12 (9.8) 0 6 (15) 2 (18.2) 2 (40) 2 (28.6)
aARR mean (SD) 0.79 (0.91) 0.80 (0.76) 0.64 (0.76) 0.46 (0.41) 1.13 (1.06) 1.78 (2.19)
Acute treatment MTP/PLEX/IVIG), n
(%)
120 (96) 61 (100) 39 (95.1) 10 (90.9) 3 (60) 7 (100)
Paraclinical features, n (%)
CSF OCB 10/107 (9.4) 1/49 (2.04) 4/36 (11.1) 3/11 (27.3) 0/5 (0) 2/6 (33.3)
CSF pleiocytosis 41/98 (41.8) 7/46 (15.2) 21/31 (67.7) 6/10 (60) 4/5 (80) 3/6 (50)
Abnormal brain MRI,
at onset
28/74 (37.8) 7/38 (18.4) 11/23 (47.8) 3/6 (50) 4/4 (100) 3/3 (100)
EDSS at the last follow-up, median
(range)
2 (0–7) 1.0 (0–4) 2 (0–7) 2 (0–4) 2.5 (1–3.5) 3.5 (0–6.5)
EDSS 0–2.5 86 (69.9) 48 (80) 26 (65) 7 (63.6) 3 (60) 2 (28.6)
EDSS 3–5.5 31 (25.2) 12 (20) 11 (27.5) 4 (36.6) 2 (40) 2 (28.6)
EDSS ≥ 6.0 6 (4.9) 0 3 (7.5) 0 0 3 (42.9)
VA at the last follow-up
VA ≥ 0.7 61/100 (61) 36/61 (59) 18/31 (58.1) – 3/3 (100) 4/5 (80)
VA > 0.2–0.6 21/100 (21) 13/61 (21.3) 8/31 (25.8) – 0 0
VA ≤ 0.2 18/100 (18) 12/61 (19.7) 5/31 (16.1) – 0 1/5 (20)
aFor ARR (SD), index event was excluded
bFive patients had an extensive transverse myelitis
cThree patients had multiphasic-ADEM with further ON relapses (ADEM-ON)
dOptico-spinal phenotypes in 4, multiple sclerosis-like phenotype in 3 patients
ON optic neuritis, NMOSD neuromyelitis optica spectrum disorder, TM transverse myelitis, ADEM-ON acute disseminated encephalomyelitis-optic neuritis, Brainstem
S brainstem syndrome, MS multiple sclerosis, Optico-spinal optico-spinal phenotype, EDSS Expanded Disability Status Scale, ARR annualised relapse ratio, SD
standard deviation, MTP methylprednisolone, PLEX plasma exchange, IVIG intravenous immunoglobulins, CSF cerebrospinal fluid, OCB oligoclonal bands, MRI
magnetic resonance imaging, VA visual acuity
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and 3 (15.8%) as second-line. Nine (47.4%) patients dis-
continued AZT: 4 for general or biological intolerance, 3
for physician or patient decision and 2 for treatment fail-
ure. AZT (n = 11 eligible for analysis) was associated with
a reduction of the mean ARR from pre-treatment, 1.05
(1.20), to on-treatment, 0.43 (0.79) (p = 0.041), and there
was no difference between pre-treatment EDSS and end-
treatment (p = 0.157). While on AZT, 6 (54.5%) patients
remained freedom of relapse, and 11 (100%) freedom of
EDSS progression (Tables 3 and 4). One patient (9%) re-
lapsed at 5.6 months after starting AZT.
Mycophenolate mophetil
Twelve (18.2%) out of 66 treated patients received
MMF; 6 of them (50%) received MMF as first-line ther-
apy, and 5 (41.7%) as second-line. MMF was discontin-
ued in 7 (58.3%) patients; 1 for general intolerance, 2
for physician decision and 4 for treatment failure. MMF
(n = 11 eligible for analysis) was associated with a re-
duction in the mean ARR from 1.20 (1.11) to 0.23
(0.60) (p = 0.033), and no changes in the EDSS were ob-
served (p = 0.317). While on MMF, freedom of relapse
was found in 8 (72.7%) patients, and freedom of EDSS
progression in 11 (100%) (Tables 3 and 4). Two patients
(16.6%) relapsed at 5 and 4.7 months after starting
MMF, respectively.
Rituximab
Thirty (45.5%) out of 66 treated patients received RTX;
19 (63.3%) of them received RTX as first-line therapy,
and 5 (16.6%) as second-line. Only one patient discon-
tinued the therapy due to general intolerance. Physician
decision and treatment failure was the reason for discon-
tinuing RTX in the other two patients. The mean ARR
was reduced from 1.08 (0.98) to 0.43 (0.89) with RTX
(n = 26 eligible for analysis), p = 0.012. Freedom of re-
lapse on RTX was observed in 19 (73.1%) patients and
freedom of EDSS progression in 23 (88.5%) (Tables 3
and 4). Among the seven patients who relapsed, three
patients (11.5%) relapsed at 1.7, 3 and 3.4 months after
starting the first infusion of RTX, respectively, and one
patient at month 5 after the last infusion.
Type II or type III IS was given to 14 (21.2%) treated
patients; type II IS as first-line in 5 (83.3%) and type III
IS in 5 (62.5%). As second-line therapy, 1 (16.6%) patient
received type II IS with MTX, and 3 (37.5%) received
type III IS with CS. Type II IS was discontinued in 6
(75%) patients, and type III IS in 5 (55.6%). Only patients
with type II IS were eligible for analysis (n = 5), and we
did not observe significant changes in ARR nor EDSS
(Tables 3 and 4).
Five (7.6%) of treated patients followed a combination
of CS with IS for a period of the disease (Additional file 1:
Table S5).
MS-DMD was administered in 10 (6.6%) treated pa-
tients (all as first-line therapy). MS-DMD was discontin-
ued in 7 (70%) patients; 4 for treatment failure and 1 for
general intolerance, physician decision and pregnancy
desire each. Three patients were switched to another MS-
DMD, and two patients to RTX and MTX. Nine patients
Fig. 2 Relapsing disease course in the 66 treated patients from the total cohort. AZT, azathioprine; MMF, mycophenolate mophetil; RTX,
rituximab; MS-DMD, multiple sclerosis disease-modifying drugs; CYC, cyclophosphamide; MTX, methotrexate; MiTX, mitoxantrone; CS, corticoids;
i.v.Ig, intravenous immunoglobulins. *Patients Id.4, Id.20, Id.60, Id.62 and Id.63 followed therapies in combination (detailed in (Additional file 1:
Table S5). **Treatment information in patients Id.2, Id.22, Id.47 and Id.66 is not depicted when started 20 years from the onset of symptoms
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Fig. 3 Kaplan-Meier analysis. a Time to relapse in the whole cohort; blue, red and black discontinuous lines represent the estimated probability of
relapsing after 1, 2 and 5 years, respectively. The 95% confidence interval is shown in grey. b, c Propensity score weighted-survival curves,
according to treatment. *The slight difference between the two analyses for the non-treated group is due to the different PS used for
each model








Patients with clinical relapse, n (%) 28 (47.5) 27 (47.4) 14 (35.0)
Time from first relapse to treatment, months, median (range) – 5.0 (0–532.6) 5.1 (0–532.6)
bTime from T0 to relapse, months, median (range) 7.9 (0.1–84.2) 15.1 (0.5–211.1) 21.9 (0.5–94.1)
Treatment duration, months, median (range) – 22.3 (6.0–176.1) 22.2 (6.0–151.0)








*PS-weighted proportional hazards Cox models were not used in the other groups due to the low number of patients
aAmong treated patients (n = 57), 9 patients were excluded since started treatment before the first relapse
bT0 was defined as the date of treatment initiation for treated patients and as the date of relapsing ADS diagnosis (date of the first relapse) for
non-treated patients
HR hazard ratio, CI confidence interval, IS immunosuppressants
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under MS-DMD were eligible for analysis (two patients
were treated with natalizumab, one with glatiramer acetate
and six with interferon) and did not show a significant re-
duction in the mean ARR or the EDSS (Table 3). Freedom
of relapse was observed in 2 (22%) patients, and freedom
of EDSS progression in 7 (77.7%) (Table 3).
Finally, there were no differences regarding the VA pre-
treatment and end-treatment in type I IS; AZT (n = 9; p =
0.289), MMF (n = 10; p = 0.564) and RTX (n = 20; p =
0.157). VA analysis was not performed in type II, type III IS
and MS-DMD subgroups since the number of patients ex-
periencing ON during the disease course was lower than 5.
Discussion
In this large cohort evaluating treatment response in
MOG-Ab adult patients with relapsing course, we found
















































AZT 19/66 (28.8) 11/19
(57.9)
2.4 (0.6–7.6) 2.1 (0.5–12.6) 1.05 (1.20)/
0.43 (0.79)
6 (54.5) 0.041 1.86 (1.30)/
1.68 (1.19)
11 (100) 0.157
MMF 12/66 (18.2) 11/12
(91.7)
1.7 (0.5–46.4) 1.7 (0.5–6.8) 1.20 (1.11)/
0.23 (0.60)
8 (72.7) 0.033 2.72 (1.69)/
2.64 (1.76)
11 (100) 0.317
RTX 30/66 (45.5) 26/30
(86.7)
3.3 (0.5–18.33) 1.7 (0.5–4.9) 1.08 (0.98)/
0.43 (0.89)
19 (73.1) 0.012 3.11 (1.83)/
2.58 (1.90)
23 (88.5) 0.096
Type II IS 6/66 (9.1) 5/6
(83.3)
5.2 (2.9–10.3) 2.0 (0.6–3.7) 0.64 (0.45)/
0.65 (0.69)
2 (40) 0.893 3.8 (1.52)/
4.0 (1.45)
1 (20.0) 0.317
Type III IS 8/66 (12.1) 3/8
(37.5)
– – – – – – – –
aMS-DMD 10/66 (6.6) 9/10
(90)
1.95 (0.5–20.1) 3.7 (1.0–14.7) 1.13 (1.38)/
0.49 (0.41)
2 (22.2) 0.374 2.5 (0.90)/
3.17 (2.15)
7 (77.7) 0.188
*Patients treated with type III IS (corticosteroids, n = 2 and intravenous immunoglobulins, n = 1) were not eligible for analysis due to treated number ≤ 5
aAmong the 9 patients with MS-DMD eligible for the analysis, 2 patients were treated with natalizumab, 1 with glatiramer acetate and 6 with interferon
FU follow-up, ARR annualised relapse ratio, SD standard deviation, EDSS Expanded Disability Status Scale, IS immunosuppressants, MS-DMD multiple sclerosis
disease-modifying drugs, AZT azathioprine, MMF mycophenolate mophetil, RTX rituximab















Therapy choice, n (%)
First line 15 (78.9) 6 (50) 19 (63.3) 5 (83.3)
(3 CYC, 1 MTX, 1 MiTX)
5 (62.5)
(3 CS, 2 IVIG)
10 (100)
(6 IFN, 1 TFN, 1 GA, 2 NTZ)





Other lines 1 (5.3) 1 (8.3) 6 (29.4) – –
Patients discontinuing treatment, n (%) 9 (47.4) 7 (58.3) 3 (10) 6 (100) 5 (55.6) 7 (70)
Causes for discontinuing treatment, n (%)
General intolerance 2 (22.2) 1 (14.3) 1 (33.3) – – 1 (14.3)
Biological intolerance 2 (22.2) – – 1 (16.7) – –
Physician decision 2 (22.2) 2 (28.6) 1 (33.3) 3 (50) 4 (80) 1 (14.3)
Patient decision 1 (11.1) – – – – –
Treatment failure 2 (22.2) 4 (57.1) 1 (33.3) 2 (33.3) 1 (20) 4 (57.1)
Pregnancy desire – – – – – 1 (14.3)
a One patient switched from CYC to MTX
bThree patients switched from MS-DMD to another MS-DMD
IS immunosuppressants, MS-DMD multiple sclerosis disease-modifying drugs, AZT azathioprine, MMF mycophenolate mophetile, RTX rituximab, CS corticoids, CYC
cyclophosphamide, IVIG intravenous immunoglobulins, MTX methotrexate, MiTX mitoxantrone, IFN interferon, TNF teriflunomide, GA glatiramer acetate,
NTZ natalizumab
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that most patients relapsed soon after disease onset, and re-
lapses were associated with a cumulative impact on long-
term disability. Importantly, first-line therapies recom-
mended by the international NMOSD guidelines had a
favourable impact on clinical outcomes.
In keeping with other studies, relapses mainly occurred
within the first year from onset of disease [9, 16]. Whether
the cumulative disability is driven by poor recovery after
onset or the relapsing course remains to be determined [9,
13]. Although our study shows an overall good prognosis,
patients who had a higher frequency of relapse displayed
worse disability at the last follow-up. This fact suggests
that a cumulative effect given by the relapsing course may
exist, underlying the need for a preventive therapy. None-
theless, only 13.6% of treated patients received immuno-
suppressants after the onset of the disease and before the
first relapse which likely reflects the current widespread
perception about the benign course of the disease. We
should note that our study deals with a cohort of exclu-
sively MOG-Ab relapsing patients, and the information
provided about the impact of relapses on disability is dif-
ferent from that observed in studies including monophasic
and relapsing patients. Further studies designed to identify
baseline prognostic factors are mandatory to select pa-
tients who will benefit from immunosuppression at the
onset of the disease.
To date, there are no standardised international guide-
lines to manage MOG-Ab-associated disease, leading to
heterogeneous policies not only regarding the type of
maintenance therapy to use but also the time to initiate
treatment [9, 16–18]. Our study shows that most physi-
cians chose therapies included in the international
guidelines for NMOSD [20, 21]. As recommended, RTX
and AZT were the most widely prescribed IS, followed
by MMF. Other IS such as CYC, MTX or MiTX, and
MS-DMD were less frequently prescribed. Moreover,
long-term CS or IVIG was not frequently used in French
and Spanish routine clinical practice, contrary to recent
trends encouraging their prescription due to the poten-
tial beneficial effect on decreasing relapses [9, 16, 18]. In
fact, evidence from previous studies suggests that effect-
iveness of immunosuppressants may be more pro-
nounced when patients are treated with oral CS during
the latency period of treatments, usually during the first
6 months [16].
The main strength of the study lies in the combin-
ation of two statistical approaches in order to evaluate
treatment response. First, we have controlled variables
which may confound treatment assignment by using PS
methods, thus, mitigating the effects of treatment indi-
cation bias. With this approach, we were able to evalu-
ate response to the most frequently IS used in clinical
practice (AZT, MMF, RTX) and we observed a reduc-
tion in the relapse risk when the patient is diagnosed
with relapsing ADS. Repeated cycles of IGIV have
shown to reduce relapses in children with relapsing
ADS and MOG-Ab [17]. Although in the present study
only a small proportion of patients were treated with
IGIV/PLEX at the acute phase, we cannot completely
exclude an impact of such treatment on the long-term
outcome. Additionally, we performed more classical
analysis to evaluate separately the effect of AZT, MMF
and RTX on relapses, confirming their beneficial effect
in reducing the ARR.
Although significant differences were obtained when
comparing treated and non-treated groups after per-
forming crude analysis, these differences were no longer
significant in PS-weighted analyses. This example under-
lines the importance of using PS methods to balance
treated and non-treated groups according to con-
founders otherwise biased results may be obtained.
AZT was mainly used as first-line therapy, while both
MMF and RTX were less frequently selected as the first
choice. Several observational studies have reported bene-
ficial effects of both AZT and MMF over the clinical
course in NMOSD [30–32]; more scarce information is
available regarding MOG-Ab-associated disease. Recent
data have shown an improvement in the ARR with the
use of both drugs [17, 18], but special attention must be
given in those patients not co-treated with corticoids
during the latency period of the drugs due to the risk of
breakthrough relapses [16]. RTX has increasingly been
used both as first-line therapy and IS-unresponsive pop-
ulations in NMOSD, leading to a sustained clinical sta-
bilisation in most patients [33–35]. Although type I IS
showed to be beneficial in decreasing ARR, none of
them improved disability except for a trend with RTX.
Doses of immunosuppressants may have an impact on
outcomes and higher doses of AZT (2–5–3mg/kg) are
potentially associated to a better response than standard
treatment (1–1.5 mg/kg) in AQP4-Ab-positive patients
[30]. Herein, patients used standard protocol with a dose
of 150mg per day. It is noteworthy that the EDSS was
evaluated at least 6 months after the relapse, and im-
provements in residual EDSS is less likely [17]. More-
over, the beneficial effect was also observed in the high
figures of freedom in EDSS progression, and this fact is
important taking into account the relatively high fre-
quency of relapse of this population.
Adherence to AZT and MMF was poor, being discontin-
ued in almost half of patients (Table 4). RTX was generally
well tolerated (only one patient discontinued due to in-
tolerance), and only two switched to another drug (MiTX
and MMF, respectively). Potential severe adverse effects
have been reported with RTX and, currently, the safety
profile suggests being cautious to prescribe this drug as
first-line therapy [36]. However, the present study was not
designed to draw conclusions regarding drug tolerance.
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A covariate balance to perform PS analysis between
type II, type III IS or MS-DMD, and non-treated groups
was not possible due to low sample numbers. However,
with the second approach, we found that neither type II
IS nor MS-DMD allowed controlling clinical activity or
cumulative disability, as previously described for MS-
DMD both in MOG-Ab-positive patients and NMOSD
[17, 37–39]. Due to the low number of patients under
MS-DMD in the present study, larger studies are needed
to confirm our results. Nonetheless, our results are in
line with other studies evaluating these drugs in MOG-
Ab-associated disease [16, 17], suggesting a lack of ef-
fectiveness of MS-DMD. In contrast to the detrimental
effect of MS-DMD in some patients with NMOSD [40],
we did not observe such an effect in our population of
adult patients with MOG-Ab.
Our study has limitations related to its retrospective
nature and the lack of randomisation for treatment allo-
cation. However, PS weighting was used to decrease in-
dication bias. Moreover, an immortal time bias could be
argued since type I IS-treated group could have pre-
sented the event before entry in the cohort (diagnosis of
relapsing ADS) which could lead to an event overesti-
mation in the non-treated group and, therefore, lower
event rates in type I IS. Covariate balance was reached
with PS analysis and, therefore, this immortal person-
time period was properly addressed [41]. On the other
hand, the cohort was not powered to analyse differences
in every treated group due to the relatively small sample
size. However, we performed two statistical methods to
analyse the effectiveness of the most widely used treat-
ments in this setting. Therapies were not prospectively
controlled and patients switched treatments over time or
had combined therapies without a washout period in
some cases which may influence treatment effectiveness
in terms of beneficial and harmful effects. We believe
that a combination of therapies did not influence the
overall results since only a few patients followed two
treatments at the same time, allowing us to evaluate the
effect of each IS.
Conclusion
This study of a large cohort of patients with relapsing
MOG-Ab-associated disease treated in real clinical prac-
tice provides several important observations: the better
outcome in terms of relapses and disability for patients
who are treated after having at least two episodes, and
the beneficial effect of being treated with immunosup-
pressants such as AZT, MMF and RTX. In addition, the
lack of effect in the patients treated with MS-DMD in
this study highlights the importance of early identifica-
tion of these patients with MOG-Ab although larger
studies are needed to confirm such finding.
Overall, the present exploratory study found good re-
sponse to type I IS, providing a rationale to investigate
efficacy of these drugs. Randomised controlled trials are
needed to obtain more definite data on optimum treat-
ment in MOG-Ab-associated disease.
The data reported here, however, are only applicable
for patients with relapsing MOG-Ab-associated disease.
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